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Background: The objective of this study is to evaluate the cost-effectiveness of a postoperative clinical care pathway
for patients undergoing major head and neck oncologic surgery with microvascular reconstruction.
Methods: This is a comparative trial of a prospective treatment group managed on a postoperative clinical care
pathway and a historical group managed prior to pathway implementation. Effectiveness outcomes evaluated were
total hospital days, return to OR, readmission to ICU and rate of pulmonary complications. Costing perspective was
from the government payer.
Results: 118 patients were included in the study. All outcomes demonstrated that the postoperative pathway group
was both more effective and less costly, and is therefore a dominant clinical intervention. The overall mean pre- and
post-pathway costs are $22,733 and $16,564 per patient, respectively. The incremental cost reduction associated with
the postoperative pathway was $6,169 per patient.
Conclusion: Implementing the postoperative clinical care pathway in patients undergoing head and neck oncologic
surgery with reconstruction resulted in improved clinical outcomes and reduced costs.Background
The treatment of head and neck squamous cell carcinoma
(HNSCC) is among the most expensive of all solid malig-
nant tumors and places a significant burden on the health-
care system [1]. The majority of the treatment expenditure
is consumed by hospitalization costs, particularly in the
postoperative period [1]. Postoperative care in these
patients is complex, with lengthy hospitalization and
recovery periods. Coordination with several health care
specialties, including nursing, physiotherapy, and respira-
tory therapists is required. Due to the growing concern
about the fiscal sustainability of health care systems around
the globe, identifying clinical interventions to improve the
cost-effectiveness of managing HNSCC is important [2].* Correspondence: jdort@ucalgary.ca
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distribution, and reproduction in any mediumA clinical care pathway is an evidence-based algorithm
designed by compiling input from multiple health care
disciplines. The pathway defines the health care milestones
that are required to provide a patient, who has a specific
diagnosis, with high quality care [3]. The pathway deter-
mines the timing and co-ordination of all essential inter-
ventions provided by multiple health care disciplines to
minimize delays, omissions and duplications and therefore
maximize effectiveness and efficiency [3,4].
The objective of this study was to evaluate the cost-
effectiveness of a postoperative clinical care pathway for
patients undergoing major head and neck oncologic sur-
gery with microvascular reconstruction. We hypothesize
that implementation of a postoperative clinical care path-
way will be cost-effective.
Methods
The study was comprised of two distinct patient popula-
tions; a historical (pre-pathway) control cohort, and the
treatment cohort of patients managed following thentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the pre-pathway group, consisting of 62 patients treated
between January 2005 and December 2009, were reviewed.
The prospective, care pathway group consisted of 56
patients who underwent head and neck oncologic resec-
tion with microvascular reconstruction between January
2011 and May 2012. Clinical outcomes data was prospect-
ively collected on this group. Patients treated between
January 2010 and December 2010 were not included, as
the care pathway was being designed, implemented and
revised during this time period. Enrollment of patients
for the treatment group began once the care pathway
was fully implemented in its final form, in order to
achieve the most accurate assessment of the pathway
effect. E.
The inclusion criteria were all patients having under-
gone resection for HNSCC, with reconstruction of the
defect performed using microvascular surgery (ie free flap
reconstruction). There were no exclusion criteria. Patients
were not excluded from the trial if their care deviated
from the guidelines laid out by the care pathway. This
allows for a pragmatic appraisal of the pathway’s efficacy.
The finalized version of the postoperative care path-
way is shown in Additional file 1. The pathway itself was
conceived and developed by fellowship-trained head and
neck oncology surgeons at the University of Calgary, with
input from other experienced health care professionals.
A design and trial period to allow staff, residents and
physicians to become aware and familiar with the path-
way occurred from January 2010 to December 2010. To
minimize potential study bias, the majority of nursing
and allied health staff were unaware of the study, with
the exception of the head and neck unit nursing manager,
and attending and resident physicians directly involved
with the study. Patients treated during this trial period
were not included in the study.
All patients were either admitted to hospital the day
of surgery, or were admitted prior to surgery due to
complications arising from the malignancy (i.e. airway
obstruction). Resection in both the control and the study
group were performed by a head and neck oncology fel-
lowship trained otolaryngologist, while reconstruction
was performed either by a plastic surgeon trained in
microvascular surgery, an otolaryngologist with micro-
vascular training, or both a plastic surgeon and an oto-
laryngologist working in conjunction. All resections and
reconstructions were performed on the same day. Fol-
lowing the surgery, patients in both groups were taken
immediately to the intensive care unit under sedation
via morphine and midazolam infusion. Patients were dis-
charged to the head and neck surgery unit once they had
been successfully weaned off ventilation support and sed-
ation. Postoperative day 1 of the care pathway was there-
fore initiated in the ICU.Data was collected on patient demographics, tumor
site, disease staging, and reconstruction performed. Out-
comes data collected included length of stay, time to
decannulation, flap failure requiring return to OR, ICU
readmission, and rate of pneumonia. Pneumonia was
selected as a key complication to be investigated, as it
is one of the more common complications seen in head
and neck surgery, and is attributed to significant mor-
bidity, increased length of stay and mortality [5-9].
Pneumonia was defined by either typical radiographic
changes or positive sputum culture, plus two of: fever,
increased oxygen requirement, or elevated white blood
cell count >11x10 [9] cells/L.
All statistical analyses were performed using Stata 12.1
(StataCorp LP, College Station, TX). Two-sided tests were
used to analyze all clinical outcomes data. Chi-squared,
Fisher’s exact, and student’s t-tests were used to analyze
the various clinical outcomes. This study received ethical
approval from The University of Calgary Conjoint Health
Research Ethics Board. Written informed consent was
obtained from all patients for the publication of this
report.
Cost collection and analysis
Costing perspective was the government payer. Intraop-
erative and postoperative costs were defined using the
time-driven activity based costing approach [10,11]. Re-
source quantification was performed by retrospective
review of the electronic medical records of each patient.
Resource unit prices were defined by reviewing the
Alberta Health Services (AHS) purchasing database, and
by contacting the AHS pharmacy, Calgary Lab Services,
and the AHS diagnostic imaging department. Practical
capacity cost rates were defined by contacting each of
the respective staffing unions and the provincial physician
fee schedule. Operative and postoperative care times were
defined by retrospective review of the nursing records.
Results
A total of 118 subjects met the inclusion criteria and
were included in the study. As shown in Table 1, patient
demographics and disease characteristics were compar-
able in both the control and study group. There were no
differences in tumor site, staging or type of reconstruc-
tion. The majority of procedures performed were oral
cavity excisions with neck dissection, and the most com-
mon reconstructive technique used was microvascular
reconstruction with radial forearm free flap.
Patients in the care pathway group had a significantly
shorter inpatient length of stay (LOS) in the postopera-
tive period, at a mean of 14.1 days compared to 21.3 days
in the pre-pathway group (p < 0.001). Time to decannu-
lation was also significantly shorter, by 5.4 days, in the
care pathway group (p < 0.001). As seen in Table 2, patients
Table 1 Frequency distribution of characteristics of patients
undergoing head and neck cancer resection with
microvascular reconstruction
Control (n = 62) Pathway (n = 56) p value
Age (mean) 62.6 62.6 ns
% (n) % (n)
Gender ns
Male 50.0 (31) 33.9
Female 50.0 (31) 66.1 (37)
Primary tumor site ns
Oral cavity 83.9 (52) 76.8 (43)
Other 16.1 (10) 23.2 (13)
Staging of disease ns
Stage I/II 22.6 (14) 32.1 (18)
Stage III/IV 75.8 (47) 66.1 (37)
Resection of mandible 35.5 (22) 39.3 (22) ns
Reconstructive type ns
Radial forearm 56.5 (35) 62.5 (35)
Fibula 19.4 (12) 12.5 (7)
Anterolateral thigh 8.1 (5) 16.1 (9)
Other free flap 16.1 (10) 8.9 (5)
ASA ns
1 6.5 (4) 5.4 (3)
2 40.3 (25) 44.6 (25)
3 48.4 (30) 42.8 (24)
4 3.2 (2) 0 (0)
No ASA recorded 1.6 (1) 7.1 (4)
Alcohol history 59.7 (37) 73.2 (41) ns
Smokers 58.1 (36) 62.5 (35) ns
COPD 22.6 (14) 23.2 (13) ns
Diabetes Mellitus 4.8 (3) 10.7 (6) ns
Dautremont et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:59 Page 3 of 6
http://www.journalotohns.com/content/42/1/59in this group also had lower rates of nosocomial pneumo-
nia, complication requiring return to ICU, and complica-
tion requiring return to OR for neck exploration, although
these reductions did not reach statistical significance.
The results of time-driven activity based costing are
shown in Table 3. Costs are broken down into inpatient
ward cost, share of return to ICU costs, and share of re-
turn to OR cost. Patients in the care pathway group hadTable 2 Post-operative outcomes in patients undergoing head an
Control (n = 62)
Mean length of stay (days) 21.3
Return to OR 16.1%
Readmission to ICU 12.9%
Mean time to decannulation (days) 13.6
Pneumonia,% (n) 30.6%a mean total cost reduction of $6,169 (27.1%) per in-
patient stay compared to the control cohort.
The intervention examined in this study, the head and
neck clinical care pathway improved all measured clin-
ical outcomes and reduced cost, when compared to the
traditional postoperative recovery experience. In terms
of cost-effectiveness analysis (CEA), this is therefore
considered a dominant clinical intervention, or quadrant
II of the cost-effectiveness plane, and is considered cost-
effective. In cases of dominant interventions, incremental
cost-effectiveness ratios do not need to be determined,
as there is no need to quantifiably measure whether out-
comes outweigh cost, or vice versa.Discussion
Our group has prospectively designed a clinical care
pathway that we have shown reduces the mean postop-
erative length of stay in this group of patients, as well as
improving other clinical outcomes. We also observed
decreased mean time to decannulation, which has been
reported to improve patient swallowing outcomes [12].
CEA of these outcomes indicates that implementation
of this care pathway both reduces cost and improves
clinical outcomes compared to the traditional postoper-
ative recovery experience.
When evaluating a new treatment method or care pat-
tern involving a multi-disciplinary care team, it import-
ant to not only measure the effectiveness of the method
in terms of clinical outcomes, but also to assess the cost
of the treatment. CEA is a useful method to determine
the most efficient way to allocate limited resources among
different interventions and methods [13,14]. To our know-
ledge, this is the first time that a head and neck clinical care
pathway has been examined for cost-effectiveness.
The surgical treatment of head and neck cancer is a
significant economic burden on the healthcare system.
The resource-intensive nature of the operative procedure
itself, along with the often complicated and prolonged
inpatient recovery contributes to this burden. The reported
rate of complications during inpatient recovery is consider-
able, and often leads to longer hospital stays, increased cost,
and increased mortality [5-9,15]. Postoperative pulmonary
complications alone have been shown to increase mortality
by 12.8% in these patients [8].d neck oncologic resection with microvascular reconstruction
Pathway (n = 56) Reduction p value
14.1 33.8% < 0.001
8.9% 44.7% 0.28
5.4% 59.5% 0.20
8.2 39.7% < 0.001
17.9% 41.5% 0.10
Table 3 Mean postoperative inpatient cost breakdown for patients undergoing head and neck oncologic resection
with microvascular reconstruction
Control (CAD) Pathway (CAD) Incremental cost (CAD) Cost reduction
Mean inpatient ward cost $15,975 $10,756 - $5219 32.7%
Mean return to OR cost $883 $310 - $573 64.9%
Mean ICU costs $5,875 $5,498 - $377 6.4%
Mean total postoperative inpatient cost $22,733 $16,564 - $6,169 27.1%
Dautremont et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:59 Page 4 of 6
http://www.journalotohns.com/content/42/1/59Clinical pathways may be an effective method of dimin-
ishing complications and reducing health care costs. Clin-
ical pathways for a variety of diagnoses and procedures
are quickly becoming standard of care at many institutions
in the United States. This is likely driven by privatization
and the underlying theme of providing quality care in the
most cost-effective manner. This has not occurred to the
same extent in Canada. To our knowledge, this is the first
clinical care pathway for head and neck surgery with
microvascular reconstruction implemented in Canada.
As the cost of Canada’s health care system continues to
rise out of proportion to its GDP, new treatment methods
and protocols should be created based on cost-effectiveness
evidence rather than theory or opinion [16,17].
There is further evidence showing that clinical care path-
ways for treating head and neck cancer maintain quality
of care while decreasing expenses in the United States.
Authors have reported savings ranging from $2,232 to
$39,419 per patient [4,18-20]. Reducing a patient’s length
of stay has been the most dominant factor in these cost
savings. The breakdown of costs associated with treat-
ment of HNSCC is dominated by hospitalization costs
[3]. These studies have shown reduction of the total
length of stay by 1.5-5 days and reduction of the average
ICU stay by 0.5 days [4,18-20]. Although statistically
negligible, these studies reported decreased postopera-
tive pneumonia, malnutrition, and readmission rates,
which could contribute to greater patient satisfaction
[4]. Clinical care pathways employed in other medical
specialties have also shown decreased ICU readmission
rates [20].
The value of a clinical care pathway lies in ensuring
that all interventions and tests are optimally scheduled,
to reduce unnecessary delays. From our experience, we
believe this translates to fewer complications and more
efficient discharge planning. Having the pathway avail-
able to all involved healthcare professionals ensures that
all are aware of the daily care and discharge planning
goals for the patient. This facilitates communication be-
tween busy healthcare providers and reduces the need
for confirming routine care through physicians, which
can lead to delays. We feel these methodological im-
provements apply across Canadian centers.
When examining what has been previously published
in the Canadian literature, outcomes in our patientstreated prior to implementation of the pathway are com-
parable to those reported by other centers. Other authors
have reported a mean length of stay of 22.9 days, time to
decannulation of 10.0 days, rate of return to the operat-
ing room of 16.0%, and rate of pneumonia of 13.3%
[12,21-23]. Additionally, mean total inpatient cost reported
by Smeele et al. was comparable to our pre-pathway cost,
at $23,600 per patient. As a result, we feel that our head
and neck cancer experience prior to implementation of
the care pathway was fairly generalizable and represen-
tative of other centers throughout the country. Clinical
care pathways may be beneficial across these centers
and provide cost-savings on a wider scale.
Beyond the operative and inpatient costs, post-discharge
costs also contribute significantly to the economic burden
of head and neck oncologic surgery. Previous studies have
shown that 56.7% of patients have at least one emergency
room visit or hospital admission in the two years following
discharge. In their U.S. study, Amonkar et al. showed this
post-discharge period translates to a mean total cost of
$85 000 USD per patient [24]. Furthermore, Funk et al.
have identified the mean total one-year cost of head and
neck surgery with free flap reconstruction to be $150 000
USD per patient, which includes the post-discharge period
[25]. We have shown the implementation of this clinical
care pathway to be cost-effective in the inpatient period,
however, cost-effectiveness in the post-discharge period
has not been demonstrated in the literature. It would be
prudent for future research to investigate whether these
patients who are discharged from hospital in a more
efficient timeline have increased healthcare utilization
or complications after discharge. Our group intends to
examine this question as part of a future study.
The potential limitations of this study include the in-
herent cost uncertainty involved in estimation models.
While we feel that the time-driven activity-based costing
model provides an acceptably low level of uncertainty, as
supported by health economics literature, we plan on
performing decision tree analysis with calculation of prob-
abilistic sensitivity analysis in the future, to further ensure
the accuracy of this costing data [26].
The pre-pathway group consisted of 62 patients treated
over a four-year time period, while the pathway group
included 56 patients over a one-year period. While this
gives the impression of an increase in patient volumes,
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is due to the fact that head and neck oncology was cen-
tralized to the study hospital in our city during this time
period. Overall patient volumes across the city were simi-
lar between the two time periods. The members and level
of experience of the clinical teams managing the patients
was similar between the two groups.
Another potential limitation arises from the fact that
the most responsible physicians (MRP’s) were unable to
be blinded to a study with this design. While this is a
potential source of bias, the care pathway largely involves
influencing clinical decisions made by other health care
providers (nursing, respiratory therapy, etc.) who were not
explicitly informed of the ongoing study. The outcomes
measurement aspect of this project was not “front and
center” for any providers and we do not believe this biased
the results. In addition, data collection was not done by
the MRP’s, but by nursing staff who were unaware of the
specifics or aims of this particular study.
Conclusion
Surgical management of HNSCC represents a substantial
economic burden on the health care system; therefore it is
important to develop innovative measures to optimize the
cost-effectiveness of our clinical interventions. This study
has demonstrated that implementation of a postoperative
care pathway in patients undergoing major head and neck
oncologic surgery with microvascular reconstruction was
cost-effective compared to those patients managed prior
to implementing the clinical pathway.
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